BioCentury

On the latest #BioCenturyThisWeek podcast: UCB’s Candid buy, Grand Rounds, biotech IPOs and the leukodystrophy pipeline buff.ly/e0mzb7r

Rather than go through with a reverse merger that would land Candid on NASDAQ, the TCE developer is taking a $2B buyout offer from UCB buff.ly/pxQhZyR

19 $1B+ M&A deals in 1H26 with nearly two months to go: A BioCentury Data Byte buff.ly/mfFoKCF

Big week for biotech M&A brings seven transactions: BioCentury Deals Report April 28-May 4 buff.ly/SFH9gvU

The latest biopharma management moves buff.ly/CKcu4kt

Proposed ban on China clinical trial data reflects deep concerns in Washington. Though unlikely to be adopted, the measure signals strong congressional interest in responding to competition from China. buff.ly/KDkju9j

In BioCentury's Finance Report: Warm receptions for Hemab, Seaport and Avalyn IPOs; follow-ons for Oruka, Veradermics and Intellia; Cue's PIPE backs in-licensing deal; and more buff.ly/sNAVw6I

As leukodystrophies approach a potential first RNA-based therapy approval, BioCentury maps 11 disease subtypes with active pipelines by modality and disease biology buff.ly/Qu4cqt9

A banker’s view from inside @US_FDA: What industry often misreads as dysfunction is rooted in the agency’s core design features — caution, independence and adherence to process — argues former Senior Advisor Peter Reikes in a BioCentury Guest Commentary buff.ly/i3iKMk8

Raising the bar on causal biology — Syncona’s Chris Hollowood in conversation with BioCentury's @FishburnSimone. How evolving discovery, and a strategic pivot, are driving Syncona’s investments thesis on gene therapies and elsewhere buff.ly/N16XWFZ

In this week's BioCentury Venture Report: A spinout from Galapagos has garnered a $125M series A; two European microbiome companies draw funding; Apuri backs a weight-loss start-up; and more buff.ly/gGPBFnG

Tiny biotech’s experience raises questions about FDA’s rare disease policies. Grace Science says it has been shut out of plausible mechanism framework, denied flexibility on CMC requirements buff.ly/J4GAy1c

Chiesi will add newly launched HAE therapy Ekterly to its rare disease portfolio through its $1.9B acquisition of KalVista buff.ly/0AY3Brk

Teva is buying venture-backed Emalex for $700M, gaining an asset for Tourette's syndrome that's nearing registration buff.ly/PzCGoex

Going rate for PRVs remains high despite pediatric program extension: A BioCentury Data Byte buff.ly/KGxLtre

Backed by $16 million in seed funding from Menlo, Aurora Therapeutics Inc. is starting with PKU as proving ground to make bespoke gene editing commercially viable. An Emerging Company Profile by @DanielleGolovin buff.ly/WqrOj7R

Kurma’s latest fundraise highlights challenges for early-stage VCs buff.ly/zGrmplX

New targets uncovered at AACR 2026. Search BioCentury's list here. buff.ly/upY2moq

In BioCentury's Deals Report: Following five other substantial M&A transactions in 2026 alone, Lilly's latest takeout is its purchase of JAK-2 developer Ajax for up to $2.3B; plus: Sun buys Organon; BeOne takes option on trispecific from Huahui; and more buff.ly/nm5AofH

Intellia’s late-stage win tees up market test case for in vivo CRISPR. BioCentury’s latest clinical report also includes updates from Inhibrx, Levicept and more buff.ly/XwwpLA1